autologous ApoB100-pulsed dendritic cell therapy (Abcentra)

N/A

Report date: 2025/01/26 19:35:48

Base Information

Drug Nameautologous ApoB100-pulsed dendritic cell therapy (Abcentra)
Drug Alias Namedendritic cells + low-density apolipoprotein B-100 therapy (CardioVax)dendritic cells + low-density apolipoprotein B-100 therapy (Abcentra)autologous cellular immunotherapy (CardioVax)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy
Mechanisms of ActionApolipoprotein B-100 modulators
TargetsApolipoprotein B-100
Therapy Area/IndicationsCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbcentra LLC
China Registration ClassN/A

Develop Information

Active CompaniesAbcentra LLC
Inactive CompaniesN/A
Active IndicationsCardiovascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A